A double-blind, randomized phase II study of once daily versus twice daily PTK787/ZK 222584 treatment in patients with advanced, previously treated metastatic adenocarcinoma of the colon or rectum

Trial Profile

A double-blind, randomized phase II study of once daily versus twice daily PTK787/ZK 222584 treatment in patients with advanced, previously treated metastatic adenocarcinoma of the colon or rectum

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2012

At a glance

  • Drugs Vatalanib (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Bayer HealthCare Pharmaceuticals
  • Most Recent Events

    • 06 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top